Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

CureVac reshapes deal with GSK, putting upfront cash toward cancer pipeline

Vaccine developer also cutting 30% of staff, adding years of cash runway

By Paul Bonanos, Director of Biopharma Intelligence
July 3, 2024 10:10 PM UTC

By revamping its deal with GSK and reducing headcount, CureVac is marshaling its resources around cancer vaccines in or nearing the clinic with a cash runway that now extends into 2028.

CureVac N.V. (NASDAQ:CVAC) will receive €400 million ($430.4 million) up front from GSK plc (LSE:GSK; NYSE:GSK) as it hands over full development and commercialization rights to mRNA vaccines to prevent COVID-19 and influenza, including seasonal and avian flu. The revised deal makes CureVac eligible for €1.05 billion in additional milestones, plus royalties. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Curevac N.V.

Gsk plc